An exploratory cross-cultural study of community-based health literacy interventions to promote the mental well-being of disadvantaged and disabled young Africans: a multi-method approach.

Background: This study explores the impact of community-based health literacy interventions on the health and mental well-being of disadvantaged young Africans in Zambia, Sierra Leone, Rwanda, and South Africa. The pandemic has exacerbated mental health problems amongst children and young people, underscoring the urgent need for equitable access to mental healthcare resources. Emphasizing the importance of equitable access to mental healthcare resources, the research addresses educational and income disparities in low- and middle-income countries (LMICs), particularly amongst young Africans with disabilities or vulnerabilities.

Editor bias and transparency in psychology's open science era.

In this open science era, psychology demands researchers be transparent in their research practices. In turn, researchers might ask if journal editors are being equally transparent in their editorial practices. Editor bias is when editors fail to be fair and impartial in their handling of articles.

On editor bias and transparency: Reply to Cowan (2024), King (2024), and Thurston and Noor (2024).

Cowan's (2024), King's (2024), and Thurston and Noor's (2024) commentaries on my article (Sharpe, 2024) find us in agreement on many matters relating to editor transparency and bias. Where we disagree is in the extent of change required and the rationale behind undertaking that change. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Purpose: Standard-of-care treatments for patients with resected stage III/IV melanoma include the immuno-oncology (IO) agents nivolumab (NIVO) and ipilimumab (IPI). This study used mixture cure models (MCMs) to estimate cure rates among patients treated with NIVO or IPI in the phase III CheckMate 238 (ClinicalTrials.gov identifier: NCT02388906) and European Organization for Research and Treatment of Cancer (EORTC) 18071 (ClinicalTrials.